TP53 and gastric cancer: Indeed, cells expressing TP53 with the R175H mutation, which is frequently observed in early‐onset GC, were more sensitive to oxaliplatin than cells expressing TP53 with the R273 mutation, which is observed more frequently in late‐onset GC (Figure 6B,C).